Mutual of America Capital Management LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 2.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 188,903 shares of the biopharmaceutical company’s stock after selling 5,566 shares during […]
Gilead Sciences (NASDAQ:GILD – Free Report) had its target price lowered by Wells Fargo & Company from $90.00 to $84.00 in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued research reports about […]
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price objective lowered by equities researchers at Wells Fargo & Company from $90.00 to $84.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target indicates a potential […]
Heritage Trust Co lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 0.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,606 shares of the biopharmaceutical company’s stock after selling 348 shares during the quarter. Heritage […]
Moors & Cabot Inc. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 6.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 21,814 shares of the biopharmaceutical company’s stock after selling 1,482 shares during the quarter. Moors […]